Due Diligence for Acquisitions
Our executive management team and expert consultants have conducted numerous types of due diligence assessments of pharmaceutical, biologics and biotech companies from start-ups to large, multisite companies to support acquisitions and investments. Our clients include law firms, venture capital and investment firms, industry partners and others. We have performed due diligence assessments to assess products and companies in all stages of development through to commercial production. We can cover all aspects of regulatory compliance (regulatory strategy to cGMP and quality system compliance) and provide sound, scientifically-based advice to potential investors and purchasers.
For more information about NSF Pharma Biotech consulting in the U.S., email firstname.lastname@example.org or call +1 202.822.1850.
For more information about NSF Pharma Biotech consulting in Europe, email email@example.com or call +44 1751 432 999.
When: September 27 - October 1, 2014 Where: Austin, TX Booth: 418 NSF Participation Elaine C. Messa, RAC, FRAPS, President,...
- 3 months ago
The long-awaited Qualified Persons template for declarations concerning Good Manufacturing Practice compliance of active substances and the accompanying guidance have...
- 4 months ago
On July 1, 2014, the Irish Medicines Board (IMB) will change its name to the Health Products Regulatory Authority (HPRA)....
- Monday, September 22, 2014
- 8:30am - 5:00pm
- York, United Kingdom
- Tuesday, September 23, 2014
- 8:30am - 5:00pm
- Manchester, UK, United Kingdom
- Tuesday, September 30, 2014
- 8:00am - 5:00pm
- Boston, Massachusetts, United States
- Thursday, October 2, 2014
- 10:00am - 11:00am
- NA, Massachusetts, United States